Sorafenib in combination with transarterial chemoembolisation in patients with unresectable hepatocellular carcinoma (TACE 2): a randomised placebo-controlled, double-blind, phase 3 trial

Supporters

Support the authors with ResearchCoin

Tip RSC

Journal

˜The œLancet. Gastroenterology & hepatology

Topics

Medicine

Cancer Oncology

Pathology

Internal Medicine

Surgery

Show all topics

DOI

10.1016/s2468-1253(17)30156-5

License

CC-BY-NC-ND

Other Formats

PDF